US3876801A - Medicine comprising lysine derivatives - Google Patents
Medicine comprising lysine derivatives Download PDFInfo
- Publication number
- US3876801A US3876801A US296583A US29658372A US3876801A US 3876801 A US3876801 A US 3876801A US 296583 A US296583 A US 296583A US 29658372 A US29658372 A US 29658372A US 3876801 A US3876801 A US 3876801A
- Authority
- US
- United States
- Prior art keywords
- lysine
- pantothenate
- medicine
- treatment
- derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title abstract description 3
- 150000002668 lysine derivatives Chemical class 0.000 title description 6
- 229940079593 drug Drugs 0.000 title 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000004472 Lysine Substances 0.000 claims abstract description 25
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims abstract description 19
- 229940014662 pantothenate Drugs 0.000 claims abstract description 19
- 235000019161 pantothenic acid Nutrition 0.000 claims abstract description 19
- 239000011713 pantothenic acid Substances 0.000 claims abstract description 19
- 210000000265 leukocyte Anatomy 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims description 9
- 201000002364 leukopenia Diseases 0.000 claims description 4
- 231100001022 leukopenia Toxicity 0.000 claims description 4
- 230000000610 leukopenic effect Effects 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000003708 ampul Substances 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 241001192665 Anous Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
Definitions
- the medicme contains lysine pantothcnate 1n sultable [56] References Cited form for re-establishing a normal figure of white blood FOREIGN PATENTS OR APPLICATIONS 87M 1/1961 France 424/319 1 cells in leukopenic patients.
- the present invention relates to a medicine based on A derivatives of lysine. and especially the pantothenate of Lysine Pammhenme g this essential amino-acid; these derivatives are utilized, Atfimmllcd exclPitfm and h i b h Distilled water Q.S.P. 5 ml accor mg to t e invention. as suita e p armaceutical 1 m 3 ampules per day preparations; they are utilized to cause stimulation of Lysine pantothenate 0.25 g different metabolic mechanisms, particularly of the Excipiem 1 com!
- the specific physiological activity of the lysine salts, Z0 1 to 2 ampule per d claimed in the present invention, is exemplified by a Th ti product i i n f th b e f group of experimental and clinical observations.
- lae can be, according to therapeutic needs, reduced up A.
- the lysine derivatives have no acute or lingering toxtioned quantities. icity.
- lysine pantothenate The administration of lysine pantothenate at suitable the LD 50 is less than 10 g/kg by oral administration, (loses to patlems 'l leukopeljlla 0f "anous enolo' and gies. causes in a relatively short time, a return to northe LD 50 is less than 8 g/kg by parenteral adminisof the leukocymry ""W' Panamtration.
- CASE NO. 1 The admi istrt ti in f th i ti 1 s. th e n h l j 't durmg L.
- Leukocytes Particularly. the administration of lysine pantothenb f after ate to a rat made leukopenic through IIIJCCIIOII of cyclotreatment treatment phosphamide (Endoxan) 40 mg/kg caused an allevia- Numcmion 3000 8000 mm of the poisonous effects. While the leukocyte nu- Polynuclears 33% 59% in rat )f the r fe ence batch remain constant dur Elsl'llphils c t e r I Lymphocytes 57% 34% mg the test. i.e. less than the initial value.
- treatment treatment I claim: Numeration 3300 7 m 1.
- a method of increasing the number of leukocytes i in a patient having leukopenia which comprises admin- Lymphocytes 62'); 2.362 istering to said patient, lysine pantothenate in an 3% amount effective to increase the leukocyte numeration of said patient.
- said lysine pantothenate is administered in a daily dose of 0.2 to 0.4 Numcrauon 6100 7 I00 P olynuclears 53! 6492 bosnwphlls 0 W 8.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The medicine contains lysine pantothenate in suitable form for re-establishing a normal figure of white blood cells in leukopenic patients.
Description
United States Patent Tixier Apr. 8, 1975 MEDICINE COMPRISING LYSINE 86M 1/1961 France 424/319 DERIVATIVES 4,048M 4/1966 France 424/319 4,465M 9/l966 France [76] Inventor: Georges Tixier, 37, avenue dlena, 1 Paris France [22] Filed; on. 11, 1972 Chemical Abstracts 75: 889505 (l97l abstracting French Patent No. 2,036,045, 12/24/70. [211 APPl- 296,583 Merck Manual (1972 pp. 300403.
[30] Foreign Application Priority Data Primary E.\'aminerStanley J. Friedman 0m. 13'. 1971 France 71.301104 Assismm 'a nerNorman A. Drezin Attorney, Agent, or Firm-Browdy and Neimark [52] US. Cl. 424/319 [51] Int. Cl. ..A61K 15/12; A6lK 27/00 57 B C [58] Field of Search 424/319. 56, 84
The medicme contains lysine pantothcnate 1n sultable [56] References Cited form for re-establishing a normal figure of white blood FOREIGN PATENTS OR APPLICATIONS 87M 1/1961 France 424/319 1 cells in leukopenic patients.
8 Claims, N0 Drawings designed for the treatment of syndromes under consideration.
1 2 MEDICINE COMPRISING LYSINE DERIVATIVES Low] and digestive preparations The present invention relates to a medicine based on A derivatives of lysine. and especially the pantothenate of Lysine Pammhenme g this essential amino-acid; these derivatives are utilized, Atfimmllcd exclPitfm and h i b h Distilled water Q.S.P. 5 ml accor mg to t e invention. as suita e p armaceutical 1 m 3 ampules per day preparations; they are utilized to cause stimulation of Lysine pantothenate 0.25 g different metabolic mechanisms, particularly of the Excipiem 1 com! tablet ones related to the formation of leukocytes. m 2 to 5 tablets per day This invention takes advantage for therapeutic purf h I l d y k f d Lys ne pantothenate 0.40 g poses 0 t e property, not area y noun. 0 some e- Exclplcm Suppository rivatives of lysine to stimulate the production of leukol m 3 PP F P I r 2. -,ln cctable preparations cytes According to another characteristic of the invention. t i pjulttfithenute g g the lysine salts which are utilized can be included into thmugh ml very different pharmaceutical recipes. allowing the intrtl-jmuscuktr n trati n proper utilization of the same for human therapeutic l m "mpuleb use.
The specific physiological activity of the lysine salts, Z0 1 to 2 ampule per d claimed in the present invention, is exemplified by a Th ti product i i n f th b e f group of experimental and clinical observations. lae can be, according to therapeutic needs, reduced up A. TOXlCO-PHARMACOLOGY to 7: or increased up to 50 71 of the above men- The lysine derivatives have no acute or lingering toxtioned quantities. icity. B CLINICALLY With respect to lysine pantothenate: The administration of lysine pantothenate at suitable the LD 50 is less than 10 g/kg by oral administration, (loses to patlems 'l leukopeljlla 0f "anous enolo' and gies. causes in a relatively short time, a return to northe LD 50 is less than 8 g/kg by parenteral adminisof the leukocymry ""W' Panamtration. CASE NO. 1 The admi istrt ti in f th i ti 1 s. th e n h l j 't durmg L. JOSEPHA 68 years old v r 5 r, 9 "5 l Physical and psychical asthenia with anorexia, loss of non an anatomo-pa o ogica examinations ave not a weight poor general condition. ruealcd any impairment of the main organic systems 3. Treatment. lysine pantothenate 090 g per day for (muscles. nervous tissues, digestive and endocrine teen days r glands ulld'excrellfl" systemslr Improvement of the general condition. psychical and The leukopenia caused by various aggressive chemih i l cal and physical agents (medical poisons and radiations) are favorably influenced experimentally by the 40 administration of lysine derivatives. Leukocytes Particularly. the administration of lysine pantothenb f after ate to a rat made leukopenic through IIIJCCIIOII of cyclotreatment treatment phosphamide (Endoxan) 40 mg/kg caused an allevia- Numcmion 3000 8000 mm of the poisonous effects. While the leukocyte nu- Polynuclears 33% 59% in rat )f the r fe ence batch remain constant dur Elsl'llphils c t e r I Lymphocytes 57% 34% mg the test. i.e.. less than the initial value. the animals Monocytes 3% 4% treated by the lysine derivatives have their number of leukocytes returning to normal and even become higher than the original value. CASE No. 2 l Thelfollowing table shows an abstract of a pharmaco- HAR' JUUA 85 years Old Ogle! test Sequelae of a fractured femur, surgically treated. PERCENTAGE OF VARIATION IN RELATION TO 5g Treatment: lysine pantothenate 0.60 g per day for ten THE REFERENCE LEUKOCYTE NUMERATIONS y Slight clinical improvement.
Batch No 4th day 6th day l lth day 13th day Batch No 1 Reference 32.35 40.5 l6.9 i 1.67 60 Leukocytes Batch No 2 before after Lysine -49.6 -26.5 +26.2 +l6.5 treatment treatment Pantothenate Numeration 3600 6600 Polynuclcai's 33% 707: Eosino hils W: Z /r Lym hocytes 63% 25% As non-restrictive examples, below are g en formula Mongcym 3% 3% CASE N 3 lowvlghat is specifically claimed in this invention is as fol- GAREL 31 years old a. the evidence ofa property of lysine and of its deriv- Disseminated sclerosis with almost a total anorexia. mi d more especially of lysine pantothenate, Treatment: lysine pantothenate 0.90 g per day for ten 5 on h f mati f hi bl d corpuscles y b. the utilization of this physiological activity for Decreased of anorexla. therapeutical purposes and more particularly in the treatment of leukopenia, and c. the utilization of the lysine derivatives in pharma- Leukocytes ceutical preparations adapted to the considered before after therapeutical uses. treatment treatment I claim: Numeration 3300 7 m 1. A method of increasing the number of leukocytes i in a patient having leukopenia which comprises admin- Lymphocytes 62'); 2.362 istering to said patient, lysine pantothenate in an 3% amount effective to increase the leukocyte numeration of said patient.
2. The method of claim 1 wherein said lysine pantothenate is administered orally.
3. The method of claim 1 wherein said lysine pantothenate is administered parenterally.
4. The method of claim I wherein said lysine panto- CASE No. 4
Cation) Treatment: 1.20 g of lysine pantothenate per day for thenate l ten duys 5. The method of claim 1 wherein said lysine pantothenate is in admixture with a pharmaceutically acceptable carrier.
6. The method of claim 2 wherein said lysine pantothenate is administered in a daily dose of 0.5 to L8 Clinical improvement.
Leukocytes I g m S- hetorc alter mmmcm mmmcm 7. The method of claim 3 wherein said lysine pantothenate is administered in a daily dose of 0.2 to 0.4 Numcrauon 6100 7 I00 P olynuclears 53! 6492 bosnwphlls 0 W 8. The method of claim 4 wherein said lysine panto- Lymphocytes 41'} 23' 1 th t d I d f 04 t l Mum.cs r; ena e is a minis ere m a at ose o o gms.
Claims (1)
1. A METHOD OF INCREASING THE NUMBER OF LEUKOCYTES IN A PATIENT HAVING LEUKOPENIA WHICH COMPRISES ADMINISTERING TO SAID PATIENT, LYSINE PANTOTHENATE IN AN AMOUNT EFFECTIVE TO INCREASE THE LEUKOCYTE NUMERATION OF SAID PATIENT.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7136804A FR2155890B1 (en) | 1971-10-13 | 1971-10-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US3876801A true US3876801A (en) | 1975-04-08 |
Family
ID=9084314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US296583A Expired - Lifetime US3876801A (en) | 1971-10-13 | 1972-10-11 | Medicine comprising lysine derivatives |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US3876801A (en) |
| BE (1) | BE789856A (en) |
| DE (1) | DE2250032C3 (en) |
| FR (1) | FR2155890B1 (en) |
| GB (1) | GB1381649A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4593044A (en) * | 1983-08-05 | 1986-06-03 | Merckle Gmbh | Injectable solution for the treatment of inflammations |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0248151A1 (en) * | 1983-05-19 | 1987-12-09 | Suntory Limited | Pantothenic acid as an antimutagenic agent |
| US4627931A (en) * | 1985-01-29 | 1986-12-09 | A. E. Staley Manufacturing Company | Method and compositions for hard surface cleaning |
| DE3744542B4 (en) * | 1987-12-30 | 2004-06-03 | Hoerrmann, Wilhelm, Dr. | Pharmaceutical use of L-δ-hydroxylysine |
| GB8922701D0 (en) * | 1989-10-09 | 1989-11-22 | Leung Lit Hung | Compositions and methods for weight reduction |
| US5635535A (en) * | 1996-04-05 | 1997-06-03 | Wagstaff; Robert K. | Method for increasing blood glucose levels |
| GB2314019B (en) * | 1996-06-10 | 2000-03-15 | Bio Scient Ltd | The use of L-Lysine in the treatment of hair loss |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR86M (en) * | 1960-07-29 | 1961-01-09 | ||
| FR87M (en) * | 1960-07-29 | 1961-01-09 | ||
| FR4048M (en) * | 1962-04-23 | 1966-04-04 | ||
| FR4465M (en) * | 1965-06-28 | 1966-09-26 | ||
| FR2036045A5 (en) * | 1969-03-03 | 1970-12-24 | Tixier Georges | Arginine pantothenate prepn |
-
0
- BE BE789856D patent/BE789856A/en unknown
-
1971
- 1971-10-13 FR FR7136804A patent/FR2155890B1/fr not_active Expired
-
1972
- 1972-10-11 US US296583A patent/US3876801A/en not_active Expired - Lifetime
- 1972-10-12 DE DE2250032A patent/DE2250032C3/en not_active Expired
- 1972-10-12 GB GB4722172A patent/GB1381649A/en not_active Expired
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR86M (en) * | 1960-07-29 | 1961-01-09 | ||
| FR87M (en) * | 1960-07-29 | 1961-01-09 | ||
| FR4048M (en) * | 1962-04-23 | 1966-04-04 | ||
| FR4465M (en) * | 1965-06-28 | 1966-09-26 | ||
| FR2036045A5 (en) * | 1969-03-03 | 1970-12-24 | Tixier Georges | Arginine pantothenate prepn |
Non-Patent Citations (2)
| Title |
|---|
| Chemical Abstracts 75:88950s (1971), & FR 2036045 A5 (24-12-1970) * |
| Merck Manual (1972), pp. 300-303. * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4593044A (en) * | 1983-08-05 | 1986-06-03 | Merckle Gmbh | Injectable solution for the treatment of inflammations |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2155890B1 (en) | 1975-04-18 |
| BE789856A (en) | 1973-02-01 |
| FR2155890A1 (en) | 1973-05-25 |
| GB1381649A (en) | 1975-01-22 |
| DE2250032A1 (en) | 1973-05-10 |
| DE2250032B2 (en) | 1974-09-19 |
| DE2250032C3 (en) | 1975-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tabor et al. | Corneal damage due to eye contact with chlorhexidine gluconate | |
| US20040097465A1 (en) | ll-12 expression controlling agents | |
| AU723812B2 (en) | Medicinal preparation and a method of medicinal action on human organism | |
| CN101347422B (en) | Uses of salvianolic acid A in preventing and/or treating diabetes and complication | |
| US3876801A (en) | Medicine comprising lysine derivatives | |
| Fiese | Treatment of Disseminated Coccidioidomycosis with Amphotericin B—Report of a Case | |
| US5155096A (en) | Method for potentiation of a therapeutic agent | |
| EP3884942B1 (en) | Use of bulleyaconitine a for treating skin disorders | |
| Brown et al. | A steady‐state evaluation of the effects of propantheline bromide and cholestyramine on the bioavailability of digoxin when administered as tablets or capsules | |
| US4990513A (en) | Antihypoxic drug and method of its application | |
| Criep et al. | Thephorin: An experimental and clinical evaluation in allergic states | |
| US20130149393A1 (en) | Medical compositions containing liquorice extracts with synergistic effect | |
| US6270756B1 (en) | Weight loss induced by alpha interferon and gamma interferon | |
| JP2023533443A (en) | Use of composition in treating stroke | |
| Chin et al. | Use of physostigmine in tricyclic antidepressant poisoning | |
| US4552865A (en) | Psychotropic drugs | |
| RU2193892C2 (en) | Method for treating myasthenia | |
| CN114099493B (en) | Active compound for inhibiting insulin resistance and application thereof | |
| US3885030A (en) | Medicine comprising lysine by-products | |
| Welsh | Failure of massive doses of vitamin B12 in acute leukaemia | |
| Carr et al. | Optimal regimens of antituberculous drugs | |
| BATTERMAN et al. | The therapeutic effectiveness and potency of digilanid in the treatment of congestive heart failure | |
| SUTRO et al. | Basis and treatment of calcification of tendinocapsular tissues, especially the supraspinatus tendon | |
| RU1827260C (en) | Method of cerebrospinal sclerosis treatment | |
| RU2003344C1 (en) | Method for burn disease treatment |